Combined Effects of Fe3O4 Nanoparticles and Chemotherapeutic Agents on Prostate Cancer Cells In Vitro

Combined Effects of Fe3O4 Nanoparticles and Chemotherapeutic Agents on Prostate Cancer Cells In Vitro

Patients with metastatic castration-resistant prostate cancer (mCRPC) have poor outcomes. Docetaxel (DTX)-based therapy is a current standard treatment for patients with mCRPC. Approaches combining conventional chemotherapeutic agents and nanoparticles (NPs), particularly iron oxide NPs, may overcom...

Full description

Bibliographic Details
Main Authors: Kanako Kojima, Sanai Takahashi, Shungo Saito, Yoshihiro Endo, Tadashi Nittami, Tadashige Nozaki, Ranbir Chander Sobti, Masatoshi Watanabe
Format: Article
Language:English
Published: MDPI AG 2018-01-01
Series:Applied Sciences
Subjects:
prostate cancer
Fe3O4 nanoparticles
carboplatin
rapamycin
reactive oxygen species
Online Access:http://www.mdpi.com/2076-3417/8/1/134

Internet

http://www.mdpi.com/2076-3417/8/1/134

Similar Items